| Drug
Discovery
Yale
Pharmaceutical Research Institute has a decades-long track
record of successful research and development of pharmaceutical
products. YPRI12 and YPRI16 are two well-known cancer treatment
agents that were discovered at YalePharma. Current research
at the Institute extends these discoveries with the design
of potent and water-soluble synthetic analogs and includes
the development of treatment agents for central nervous system
disorders.
Discovery
at YalePharma is driven by basic research that yields a wealth
of lead compounds. Many of these come from natural products
research, as was the case with the discovery of YPRI80 and
YPRI88. Alternatively, leads are based on information obtained
from fundamental studies of biochemical mechanisms of action.
Combinatorial methodologies and computer-aided drug design
complement YalePharma's approach to discovery of lead compounds
and their refinement into innovations.
YalePharma
consists of research programs in the areas of structure-based
and computational drug design, synthetic medicinal chemistry,
combinatorial chemistry, total & multistep synthesis,
and chemical process development & optimization. Including:
High Throughput Screening, Medicinal and Combinatorial Chemistry
and Synthesis and Process Development.
Discovery
Capabilities
YalePharma's
scientists perform the following services:
Pharmaceutical
research -
Drug
discovery,design, and development
-
Structure-activity
relationships
-
Combinatorial
chemistry
-
Organic design and synthesis
-
Mass and radioisotopically labeled compounds
-
Natural products chemistry
-
Compound separation, purification, and characterization.
Current
Discovery Project
-
Cancer chemotherapy
-
Male
contraception
-
Biochemical
mechanisms of action in the central nervous system (CNS)
-
Prevention
and treatment of CNS disorders such as AIDS dementia, Alzheimer's
disease, addiction, and schizophrenia
-
Agents
to prevent stroke
-
AYPRIficial enzymes for chemoprotective applications
-
Pharmacological
and biological probes, such as imaging agents
-
Immune
suppression and promotion.
Multiplex
Assay Development
|
